Revolutionizing Legal Billing with Transparent Data by Law Firm & Practice Area
Using state of the art software, AI, and expert legal research, the Legal Pricing Platform identifies, parses and uploads hourly rates that are publicly disclosed, from over 100 sources, of Attorneys and Support Staff at over 3,000 law firms representing over 20,000 companies in 63 countries with rates denominated in 12 currencies. Secondary public records research is performed to complete detailed engagement profiles of the Attorneys and companies involved.
Article content
Through this process the Platform is able to provide actionable and monetizable data to our client community – large law firms, corporations and consulting firms to make:
Article content
Direct comparisons between Attorneys and firms (as opposed to general averages of a collection of various firms' rates as found in surveys, e-billing services or online auction sites) and
Important pricing and strategy decisions enterprise-wide or engagement-by-engagement for litigation, transactional, advisory and regulatory matters.
Article content
In the Legal Pricing Platform, all hourly rates, hours and fees for each individual Attorney are cited as to the source. For example, the citation for a court filing includes Case Name, Case Number, Court, Case Filing Date, Filing Number, Filing Description, Attorney and Support Staff listed by Full Name, Client Name, Hourly Rate (Standard, Billed and Discount) of each Timekeeper, Hours Billed, Total Hours and the time period in which the work was performed. As mentioned, further secondary research is required to confirm Attorney experience levels (Graduation and Bar licensure years), Bar State (in the United States) or Bar Country (outside of the United States), Practice Area(s) and primary industry of the Client and Fortune 500 / Global 500 Rank of the Client.
Article content
Data for all Analytical Reports is downloaded from the Platform and rates are detailed as Average Billed Rates by Annual Revenue Rankings (AMLAW 10, 50, etc.), Firm, Position (Senior Partner: 25 years or more since Graduation Year, Partner: 24 years or less, Counsel, Senior Associate: 5 years or more, Associate: 4 years or less and Support Staff), Practice(s) and Rate Years. Some rates were estimated.
Article content
In order to provide this detailed level of clarity and transparency, the Platform finds rate information in 1) public records in US Federal Courts: Supreme Court of the United States, Appellate Courts including the Federal Circuit, District Courts, Bankruptcy Courts, Tax Court and Others 2) US State Courts 3) publicly available budgets from Municipalities, Districts (School, Water, Environmental and Others), counties and states where attorneys were hired to perform legal work for the public entity 4) registrations and legal services agreements such as SEC records and other publicly disclosed departmental or agency filings.
Article content
Since the publisher researches, reviews, and analyzes only publicly available information and cites the source of the information, the United States federal and state court systems easily recognize and accept the validity and veracity of the data in court. The data has been used and cited in several hundred United States federal and state court cases, including the Supreme Court of the United States, Federal District Courts, Appellate Courts, including the Federal Circuit, Federal Bankruptcy and Adversary proceedings, US Tax Court, and major State Litigation Courts. Additionally, the data has been utilized in private arbitrations (AAA and JAMS) and in the United Kingdom.
Article content
Bennett Jones LLP
Bankruptcy/Restructuring/Reorganization
Commercial Litigation
Corporate/Corporate Transactions & Securities
Finance
Labor & Employment
Mergers & Acquisitions
Tax
Blake, Cassels & Graydon LLP
Bankruptcy/Restructuring/Reorganization
Class Action
Commercial Litigation
Corporate/Corporate Transactions & Securities
Employee Benefits
Finance
Labor & Employment
Mergers & Acquisitions
Pension & Welfare
Real Estate
Tax
Borden Ladner Gervais LLP
Bankruptcy/Restructuring/Reorganization
Commercial Litigation
Corporate/Corporate Transactions & Securities
Finance
Labor & Employment
Mergers & Acquisitions
Cassels Brock & Blackwell LLP
Bankruptcy/Restructuring/Reorganization
Equities
Finance
Private Equity
Tax
Technology including Emerging Technology
Dentons
Bankruptcy/Restructuring/Reorganization
Commercial Litigation
Corporate/Corporate Transactions & Securities
Finance
Mergers & Acquisitions
Securities
Goodmans, LLP
Bankruptcy/Restructuring/Reorganization
Commercial Litigation
Corporate/Corporate Transactions & Securities
Finance
Labor & Employment
Mergers & Acquisitions
Real Estate
Tax
Gowling WLG
Alternative Dispute Resolution
Bankruptcy/Restructuring/Reorganization
Commercial Litigation
Corporate/Corporate Transactions & Securities
Environmental
Finance
Intellectual Property
Labor & Employment
Mergers & Acquisitions
Real Estate
Securities
Tax
McCarthy Tetrault LLP
Antitrust
Bankruptcy/Restructuring/Reorganization
Capital Markets
Commercial Litigation
Compensation/Executive Compensation
Corporate Governance
Corporate/Corporate Transactions & Securities
Employee Retirement Income Security Act of 1974
Finance
Human Resources/Personnel
Labor & Employment
Mergers & Acquisitions
Securities
Tax
McMillan LLP
Arbitration/Mediation
Bankruptcy/Restructuring/Reorganization
Capital Markets
Class Action
Commercial Litigation
Corporate/Corporate Transactions & Securities
Finance
Securities
Trademark
Miller Thomson LLP
Arbitration/Mediation
Bankruptcy/Restructuring/Reorganization
Commercial Litigation
Communications
Corporate/Corporate Transactions & Securities
Creditor Rights
Cyber Security
Mergers & Acquisitions
Privilege Review
Supreme Court & Appellate
Osler, Hoskin & Harcourt LLP
Bankruptcy/Restructuring/Reorganization
Capital Markets
Class Action
Commercial Litigation
Corporate/Corporate Transactions & Securities
Finance
Labor & Employment
Litigation Support Services
Mergers & Acquisitions
Real Estate
Research
Securities
Tax
Stikeman Elliott LLP
Alternative Dispute Resolution
Bankruptcy/Restructuring/Reorganization
Capital Markets
Class Action
Commercial Litigation
Communications
Corporate/Corporate Transactions & Securities
Employee Benefits
Environmental
Finance
Insurance
Labor & Employment
Mergers & Acquisitions
Private Equity
Real Estate
Securities
Tax
Thornton Grout Finnigan LLP
Bankruptcy/Restructuring/Reorganization
Commercial Litigation
Creditor Rights
Finance
Torys, LLP
Bankruptcy/Restructuring/Reorganization
Capital Markets
Commercial Litigation
Corporate/Corporate Transactions & Securities
Finance
Food & Alcohol Industry
Intellectual Property
Labor & Employment
Mergers & Acquisitions
Patent
Pension & Welfare
Private Equity
Real Estate
Securities
Tax
Article content
Section 2: City Hourly Rates by Law Firm
Article content
Bennett Jones LLP
Calgary
Montreal
Toronto
Vancouver (Canada)
Blake, Cassels & Graydon LLP
Calgary
Montreal
Toronto
Vancouver (Canada)
Borden Ladner Gervais LLP
Montreal
Toronto
Vancouver (Canada)
Cassels Brock & Blackwell LLP
Calgary
Toronto
Dentons
Ottawa
Toronto
Goodmans, LLP
Toronto
Gowling WLG
Calgary
Ottawa
Vancouver (Canada)
McCarthy Tetrault LLP
Montreal
Quebec City
Toronto
Vancouver (Canada)
McMillan LLP
Toronto
Miller Thomson LLP
Toronto
Osler, Hoskin & Harcourt LLP
Ottawa
Toronto
Stikeman Elliott LLP
Montreal
Toronto
Thornton Grout Finnigan LLP
Toronto
Torys, LLP
Calgary
Montreal
Toronto
Article content
For more information about this report visit https://www.researchandmarkets.com/r/sypk4k About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies
DelveInsight's, ' Cystic fibrosis Pipeline Insight, 2025 ' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Cystic fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cystic Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Cystic Fibrosis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Cystic Fibrosis Pipeline Outlook Report Key Takeaways from the Cystic Fibrosis Pipeline Report In July 2025, Enterprise Therapeutics Ltd announced a study is the first to give ETD001 to people with CF. The study will be run in two parts. Part A will assess if ETD001 is safe to give to people with CF, and Part B will assess if ETD001 improves lung function. The study drug is taken twice a day, in Part A it is taken for 7 days and in Part B for 28 days. In Part B there will be a separate period where dummy medicine is given for 28 days so the treatments can be compared. In July 2025, Vertex Pharmaceuticals Incorporated conducted a study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. DelveInsight's Cystic Fibrosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Cystic Fibrosis treatment. The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Promising Cystic fibrosis Pipeline Therapies such as Tigerase®, Pulmozyme®, danazol, Brensocatib, SPL84, ETD001, ELX/TEZ/IVA, BI 3720931, JBT-101 (lenabasum) and others. Discover how the Cystic Fibrosis treatment paradigm is evolving. Access DelveInsight's in-depth Cystic Fibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Cystic Fibrosis Clinical Trials and Studies Cystic Fibrosis Emerging Drugs Profile VX-121: Vertex Pharmaceuticals VX-121 and tezacaftor are designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the CFTR protein. VX-561 (deutivacaftor) is a potentiator designed to keep CFTR proteins at the cell surface open longer to improve the flow of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways. The triple combination of VX-121/tezacaftor/VX-561 is being developed as an investigational once-daily treatment for people with CF with certain mutations in the CFTR gene. It is currently being investigated in Phase III stage of development. Brensocatib: AstraZeneca Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. The drug is currently being evaluated in Phase II clinical trial to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug. ELX-02: Eloxx Pharmaceuticals ELX-02 is an investigational compound being developed as a therapy for genetic diseases caused by nonsense mutations such as cystic fibrosis. Structurally, ELX-02 is an aminoglycoside analogue that induces read-through of nonsense mutations through interaction with the ribosome, resulting in the production of full-length functional proteins. The therapy was designated an orphan drug in the US, an orphan medicinal product in Europe, and given fast track designation in the US. ELX-02 is being tested in CF patients carrying least one G542X mutation in two parallel open-label Phase II clinical trials. S-1226: SolAeroMed Inc. S1226 is SolAeroMed's lead therapy. S1226 is formulated to rapidly reopen constricted, mucus plugged airways, and should increase the effectiveness of respiratory drug delivery. The S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient's constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways. SolAeroMed is currently conducrting a phase II clinical trial in cystic fibrosis. The Cystic Fibrosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment. Cystic Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market Explore groundbreaking therapies and clinical trials in the Cystic Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Cystic Fibrosis Drugs Cystic Fibrosis Companies Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Cystic fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Cystic Fibrosis Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspectives Scope of the Cystic Fibrosis Pipeline Report Coverage- Global Cystic Fibrosis Companies- Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Cystic fibrosis Pipeline Therapies- Tigerase®, Pulmozyme®, danazol, Brensocatib, SPL84, ETD001, ELX/TEZ/IVA, BI 3720931, JBT-101 (lenabasum) and others. Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Cystic Fibrosis drug development? Find out in DelveInsight's exclusive Cystic Fibrosis Pipeline Report—access it now! @ Cystic Fibrosis Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Cystic Fibrosis: Overview Pipeline Therapeutics Therapeutic Assessment Cystic Fibrosis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug name: Company Name Drug profiles in the detailed report….. Mid-Stage Products (Phase II) AP-PA02: Armata Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) VX-522: Vertex Pharmaceuticals Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SPL23: SpliSense Drug profiles in the detailed report….. Inactive Products Cystic Fibrosis -Key Companies Cystic Fibrosis -Key Products Cystic Fibrosis - Unmet Needs Cystic Fibrosis - Market Drivers and Barriers Cystic Fibrosis - Future Perspectives and Conclusion Cystic Fibrosis -Analyst Views Cystic Fibrosis- Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
4 hours ago
- Globe and Mail
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company's Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom's largest provider of occupational health services, where he led the company's technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX's UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality's direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world's largest wellness platform. As MedX's CEO, Gevisser will focus on expanding MedX's international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities. 'John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX's operations,' said Mike Druhan, MedX President, Dermatology Services. 'His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success.' 'Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism,' said John Gevisser. 'As a former client, I saw firsthand how seamlessly MedX's hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance.' While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. 'The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time,' said Ken McKay, Chairman of the Board. About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy ® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit:
CBC
5 hours ago
- CBC
Green energy has passed 'positive tipping point,' and cost will come down, UN says
The global switch to renewable energy has passed a "positive tipping point" where solar and wind power will become even cheaper and more widespread, according to two United Nations reports released on Tuesday that describe a bright spot amid otherwise gloomy progress to curb climate change. Last year, 74 per cent of the growth in electricity generated worldwide was from wind, solar and other green sources, according to the UN's multi-agency report, called Seizing the Moment of Opportunity. It found that 92.5 per cent of all new electricity capacity added to the grid worldwide in that time period came from renewables. Meanwhile, sales of electric vehicles are up from 500,000 in 2015 to more than 17 million in 2024. The three cheapest electricity sources globally last year were onshore wind, solar panels and new hydropower, according to an energy cost report by the International Renewable Energy Agency (IRENA). Solar power now is 41 per cent cheaper and wind power is 53 per cent cheaper globally than the lowest-cost fossil fuel, the reports said. Fossil fuels, which are the chief cause of climate change, include coal, oil and natural gas. "The fossil fuel age is flailing and failing," UN Secretary General Antonio Guterres said in a Tuesday morning speech unveiling the reports. "We are in the dawn of a new energy era. An era where cheap, clean, abundant energy powers a world rich in economic opportunity. "Just follow the money," Guterres said, quoting the reports that showed last year there was $2 trillion US in investment in green energy, which is about $800 billion US more than in fossil fuels. Renewables grow despite high fossil fuel subsidies Still, UN officials said the switch to renewable energy, while remarkable compared with 10 years ago, is not happening fast enough. The global renewables growth has been mostly in developed countries such as China — where one-10th of the economy is tied up in green energy — as well as countries such as India and Brazil. Yet Africa represented less than two per cent of the new green energy capacity installed last year despite having great electrification needs, the reports said. UN officials blamed the high cost of capital for the Global South. "The Global South must be empowered to generate its own electricity without adding to already unsustainable level of debts," said Bahamian climate scientist Adelle Thomas of the Natural Resources Defence Council. Thomas, who did not work on the reports, added that they debunk the myth that clean energy cannot compete with fossil fuels, instead showing a clean energy future is not just possible but likely inevitable. The UN reports are "right on the money," said Jonathan Overpeck, dean of the University of Michigan's school for environment and sustainability. Overpeck, who also wasn't part of the studies, said the economic tipping point leads to a cycle that keeps driving renewable costs down and makes fossil fuel power less and less desirable. Renewables are booming despite fossil fuels getting nearly nine times the government consumption subsidies as they do, Guterres and the reports said. In 2023, global fossil fuel subsidies amounted to $620 billion US, compared with $70 billion US for renewables, the UN said. But just as renewables are booming, fossil fuel production globally is still increasing, instead of going down in response. UN officials said that's because power demand is increasing overall, spurred by developing countries, artificial intelligence data centres and the need for cooling in an ever-warmer world. "A typical AI data centre eats up as much electricity as 100,000 homes," Guterres said, calling on the world's major tech firms to power data centres completely with renewables by 2030. "By 2030, data centres could consume as much electricity as all of Japan does today." Solar and wind power programs cut in U.S. In the United States, solar and wind power had been growing at a rate of 12.3 per cent a year from 2018 to 2023, the IRENA report said. But since President Donald Trump took office in January, his administration has withdrawn the nation from the landmark Paris Agreement on climate change and cut many federal renewable energy programs, with a renewed emphasis on fossil fuels. Guterres warned nations hanging on to fossil fuels that they were heading down a dangerous path that would make them poorer, not richer, without naming the U.S. specifically. "Countries that cling to fossil fuels are not protecting their economies, they are sabotaging them. Driving up costs. Undermining competitiveness. Locking in stranded assets," he said. Renewables are the smart way to go for energy security, Guterres said. With renewables, "there are no price spikes for sunlight. No embargoes on wind." WATCH | Wind power is projected to increase B.C.'s power grid: How wind power is projected to boost B.C.'s power grid 6 months ago In B.C., nine new wind farms promise to boost the province's power grid by eight per cent, with the province pledging to speed up the permitting process for renewable energy projects. Radio-Canada's Camille Vernet takes us to a working wind farm to explain the challenges and opportunities people are seeing.
